(CIX: WRAL30)  1,126.59  up arrow+2.55  (0.23 %)  Updated: 08:10 PM EST, Dec 19 2014
(NQ: Apple)  111.78  down arrow-0.87  (-0.77 %)  Updated: 08:10 PM EST, Dec 19 2014
(NY: QUINTILES)  60.39  up arrow+1.01  (1.7 %)  Updated: 06:40 PM EST, Dec 19 2014
(OP: BASF SE)  85.15  down arrow-1.55  (-1.78 %)  Updated: 05:20 PM EST, Dec 19 2014
(NQ: BioCryst)  11.16  up arrow+0.08  (0.68 %)  Updated: 08:10 PM EST, Dec 19 2014
(NQ: BioDelivery)  13.82  up arrow+0.76  (5.82 %)  Updated: 08:10 PM EST, Dec 19 2014
(NQ: CEMP)  21.31  up arrow+0.8  (3.9 %)  Updated: 08:10 PM EST, Dec 19 2014
(NQ: Cisco Systems)  27.77  up arrow+0.12  (0.43 %)  Updated: 08:10 PM EST, Dec 19 2014
(NQ: Cree)  31.21  up arrow+0.31  (1 %)  Updated: 08:10 PM EST, Dec 19 2014
(NQ: DARA)  0.88  up arrow+0.04  (4.3 %)  Updated: 08:10 PM EST, Dec 19 2014
(NY: EMC CORPORATION)  30.14  up arrow+0.19  (0.63 %)  Updated: 06:40 PM EST, Dec 19 2014
(NQ: Extreme Networks)  3.44  up arrow+0.09  (2.69 %)  Updated: 08:10 PM EST, Dec 19 2014
(NQ: FB)  79.88  up arrow+1.48  (1.89 %)  Updated: 08:10 PM EST, Dec 19 2014
(NY: GLAXOSMITHKLINE)  43.35  up arrow+0.06  (0.14 %)  Updated: 06:40 PM EST, Dec 19 2014
(NQ: GOOG)  516.35  up arrow+5.25  (1.03 %)  Updated: 08:10 PM EST, Dec 19 2014
(NY: IBM)  158.51  up arrow+0.83  (0.53 %)  Updated: 06:40 PM EST, Dec 19 2014
(NY: LH)  105.80  down arrow-0.64  (-0.6 %)  Updated: 06:40 PM EST, Dec 19 2014
(OP: Lenovo Group)  26.38  up arrow+0.82  (3.21 %)  Updated: 05:20 PM EST, Dec 19 2014
(NY: MRK)  59.58  up arrow+0.6  (1.02 %)  Updated: 06:40 PM EST, Dec 19 2014
(NQ: Microsoft Corp)  47.66  up arrow+0.14  (0.29 %)  Updated: 08:10 PM EST, Dec 19 2014
(NQ: NTAP)  42.94  up arrow+0.22  (0.52 %)  Updated: 08:10 PM EST, Dec 19 2014
(NY: NOVARTIS AG)  94.61  up arrow+0.04  (0.04 %)  Updated: 06:40 PM EST, Dec 19 2014
(OP: Novozymes A/S)  43.11  down arrow-0.32  (-0.73 %)  Updated: 05:20 PM EST, Dec 19 2014
(NY: PFIZER)  31.94  down arrow-0.03  (-0.09 %)  Updated: 06:40 PM EST, Dec 19 2014
(NQ: Pozen)  8.17  up arrow+0.27  (3.42 %)  Updated: 08:10 PM EST, Dec 19 2014
(NY: RED HAT)  68.04  up arrow+6.54  (10.63 %)  Updated: 06:40 PM EST, Dec 19 2014
(NQ: BBRY)  9.99  down arrow-0.08  (-0.79 %)  Updated: 08:10 PM EST, Dec 19 2014
(NQ: Salix)  117.20  down arrow-1.25  (-1.06 %)  Updated: 08:10 PM EST, Dec 19 2014
(NQ: SQI)  14.97  down arrow-0.09  (-0.6 %)  Updated: 08:10 PM EST, Dec 19 2014

Posts tagged “Pozen”

Updated May 8, 2013

Premium Lock Latest pain for Pozen: AstraZeneca to stop sales of its pain reliever in US

Pozen The Chapel Hill-based pharmaceutical firm discloses in its quarterly financial report that a big drug partner is going to stop selling the company's big money maker in the U.S. and parts of Europe. What does this mean for Pozen and its shareholders?

March 27, 2013

Premium Lock Safer aspirin from Pozen filed for FDA approval

FDA A safer-on-the-stomach aspirin developed by Pozen has been submitted to the Food and Drug Administration for regulatory approval

Updated March 12, 2013

Premium Lock Pozen's drug combination patent maintained in Europe

Pozen CEO John Plachetka European patents for Pozen's combination drug technology are valid and will continue to stand, according to a decision issued by European patent authorities.

March 6, 2013

Premium Lock Pozen pain reliever sales, royalties surge in 2012

Pozen Sales of Vimovo, a pain reliever sold by partner AstraZeneca, surged in 2012, thus delivering a growing revenue stream to Chapel Hill-based Pozen. But the company still posted a $25 million dollar loss.

November 8, 2012

Premium Lock Earnings: Salix; PowerSecure; Pozen; BioCryst

Bulldog Inside the Bulldog Blog: Revenues up at Salix; record revenues for PowerSecure; Pozen cuts losses; net loss declines at Biocryst;

November 7, 2012

Premium Lock Pozen reports positive test results for proposed aspirin therapy

Pozen Results from two Phase 3 clinical trials for its proposed aspirin therapy are positive, Chapel Hill-based Pozen says.

October 2, 2012

Premium Lock Pozen prevails in patent fight over pain killer

Treixmet The Chapel Hill-based pharmaceutical firm has already sold future royalty rights and milestone payments that it would have received from GlaxoSmithKline for $75 million.

August 24, 2012

Premium Lock Pozen won't need new trial for proposed safer aspirin

Pozen's headaches After discussions with the FDA, the Chapel Hill-based drug firm says its safer form of aspirin could be ready for a drug filing in the first half of 2013.

June 21, 2012

Premium Lock FDA wants more tests on proposed Pozen heart drug

FDA The Chapel Hill drug developer says the FDA wants more information on PA32540, an aspirin combination drug developed to deliver the cardiovascular benefits of aspirin in a way less likely to cause stomach irritation characteristic of aspirin alone.

May 8, 2012

Premium Lock Pozen migraine drug licensed to Desitin for commercialization in Europe

Pozen The migraine headache treatment developed by Pozen now has a partner for commercialization in Europe.

May 1, 2012

Premium Lock Pozen losses increase but arthritis drug royalties grow

Pozen The Chapel Hill-based drug firm reports a loss of $8.4 million for the first quarter, up from $5.7 million a year ago. However, sales of the arthirtis drug Vimovo are growing.

April 30, 2012

Premium Lock Pozen runs into a headache with FDA over safer aspirin

Pozen's headache During a recent meeting with the FDA to discuss its submission, the agency suggested the Chapel Hill-based company also seek approval for the drug at a lower dose

Updated March 22, 2012

Premium Lock Pozen shares surge on aspirin therapy trial news

The Chapel Hill-based pharmaceutical firm says its compound redcues gastric ulcers in two Phase 3 trials of patients who are taking aspirin daily. Pozen plans a new drug application in the third quarter. PLUS: Two board memebers leaving.

Diagram from Pozen presentation about PA technology Diagram from Pozen presentation about PA technology

December 22, 2011

Premium Lock Pozen strikes manufacturing pact with Patheon for heart drug

Patheon logo Pozen's new cardiovascular drug does not even have a name yet, but it has a manufacturer to produce it once it gets U.S. Food and Drug Administration approval.

November 28, 2011

Premium Lock Pozen's $75M deal - It's all about cash for product pipeline

Treixmet The money strengthens Pozen's negotiating position as it seeks a partner for a drug under development and does so without diluting Pozen's shareholders, CEO John Platchetka

Updated November 28, 2011

Premium Lock Pozen sells royalty rights to migraine drug for $75M

Treixmet Treximet is marketed in the United States by Pozen drug partner GlaxoSmithKline. The royalty rights were purchased by a Canadian pension plan.

Updated November 6, 2011

Premium Lock Pozen CEO criticizes partner AstraZeneca for slow drug sales

Pozen "Although last quarter's U.S. net sales were up from the second quarter, the $13.4 million year to date total is well below what we think Vimovo is capable of selling so AstraZeneca has work to be done to make that better," John Platchetka says.

November 3, 2011

Premium Lock Tech earnings: Pozen, DexOne, Biocryst, Furiex, Targacept

Earnings    It's been a busy earnings week, and five North Carolina firms all reported losses.

September 8, 2011

Premium Lock Losers in Treximet patent decision are appealing

Pozen A securities filing by patent-holder Pozen says that generic drug-makers are appealing a ruling by a judge in that Pozen had exclusive rights to Treximet.

Tags: Pozen, GSK
Techwire Inside Partners
The Skinny: A Blog by Rick Smith


Frank Vinluan
Life science
Vivek Wadhwa
Dr. Mike Walden
Tech economy